Table 2 Multivariate analysis of NLR determined by ROC for patients with advanced NPC
Endpoint | Variable | HR | 95% CI for HR | P value |
|---|---|---|---|---|
OS | ||||
Age (≤ 45 vs. > 45) | 1.69 | 1.29–2.22 | < 0.001 | |
Sex (Male vs. Female) | 1.30 | 0.90–1.87 | 0.163 | |
Smoking history (No vs. Yes) | 1.11 | 0.83–1.49 | 0.492 | |
T stage (T1–2 vs. T3–4) | 1.34 | 0.98–1.85 | 0.071 | |
N stage (N0–1 vs. N2–3) | 2.86 | 2.19–3.73 | < 0.001 | |
NLR (≤ 2.50 vs. > 2.50) | 1.72 | 1.31–2.24 | < 0.001 | |
Treatment (RT alone vs CCRT) | 1.43 | 0.82–2.50 | 0.213 | |
Treatment (RT alone vs NACT+CCRT) | 1.23 | 0.70–2.14 | 0.472 | |
DMFS | ||||
Sex (Male vs. Female) | 1.34 | 0.95–1.90 | 0.097 | |
N stage (N0–1 vs. N2–3) | 3.50 | 2.65–4.63 | < 0.001 | |
NLR (≤ 2.50 vs. > 2.50) | 1.45 | 1.10–1.92 | 0.009 | |
LRFS | ||||
Age (≤ 45 vs. > 45) | 1.40 | 1.02–1.92 | 0.035 | |
N stage (N0–1 vs. N2–3) | 1.35 | 0.97–1.88 | 0.077 | |
PFS | ||||
Age (≤ 45 vs. > 45) | 1.44 | 1.16–1.79 | 0.001 | |
Family history (No vs. Yes) | 1.17 | 0.91–1.50 | 0.213 | |
Smoking history (No vs. Yes) | 1.12 | 0.90–1.39 | 0.323 | |
T stage (T1–2 vs. T3–4) | 1.27 | 0.99–1.62 | 0.063 | |
N stage (N0–1 vs. N2–3) | 2.25 | 1.81–2.79 | < 0.001 | |
NLR (≤ 2.50 vs. > 2.50) | 1.29 | 1.04–1.59 | 0.021 | |